Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;2011(1):7.
doi: 10.1186/1687-9856-2011-7. Epub 2011 Jul 12.

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study

Peter A Lee  1 , E Kirk Neely, John Fuqua, Di Yang, Lois M Larsen, Cynthia Mattia-Goldberg, Kristof Chwalisz
Affiliations

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study

Peter A Lee et al. Int J Pediatr Endocrinol. 2011.

Abstract

Introduction: Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice for CPP. We investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1-month depot for CPP.

Methods: This prospective, open-label study had a long-term, observational, follow-up period. Forty-nine females and 6 males were enrolled. Leuprolide acetate depot was administered intramuscularly every 28 days. Height and growth rate during and after treatment until adulthood were measured.

Results: Among 30 of 49 females having an adult height (AH) measurement, 29 had target heights available (mean = 163.8 cm) and 27 had pretreatment predicted adult heights (PAHs; mean = 157.4 cm). After treatment, the mean AH at mean age 21.8 years [range 13.7-26.7 years] was 162.5 cm, a mean height gain over baseline PAH of 4.0 cm. The mean height standard deviation score was -0.1 at AH.

Conclusions: Treatment of CPP with leuprolide acetate 1-month depot had beneficial effects on growth rate and preservation of AH.

Trial registration: ClinicalTrials.gov: NCT00660010.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition. Flow of female patients through the trial. Patients may have had more than one reason for treatment discontinuation.
Figure 2
Figure 2
Mean ± SE growth rates for females. Incremental growth rates were calculated every 6 months. The baseline growth rate was defined as the growth rate for 1 year prior to the start of study drug. Numbers reflect available results.
Figure 3
Figure 3
Change in bone age to change in chronological age during each year of treatment for females. The ratio of the change in BA from the previous visit to the change in CA from the previous visit was calculated at approximately one year intervals. Numbers reflect available results.
Figure 4
Figure 4
Height outcomes for females during the study. Adult height includes data from patients whose height was collected at adulthood after age 18. For patients who were missing adulthood height data, adult height was established when their growth velocity was <1 cm/year or bone age was ≥14 years during the follow-up period.
Figure 5
Figure 5
Height standardized scores for females during the study. The pretreatment baseline is the mean standardized height score of patients before initiation of leuprolide acetate therapy. The height at the end of treatment refers to the mean standardized height score for patients at the end of the treatment period. Adult height includes standardized scores for those patients whose height was collected at adulthood after age 18. For those without adult height available, adult height was established when their growth velocity was <1 cm/year or bone age was ≥14 years during the follow-up period.
See this image and copyright information in PMC

References

    1. Brauner R. Central precocious puberty in girls: prediction of the aetiology. J Pediatr Endocrinol Metab. 2005;18(9):845–7. doi: 10.1515/JPEM.2005.18.9.845. - DOI - PubMed
    1. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F. et al.Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752–62. doi: 10.1542/peds.2008-1783. - DOI - PubMed
    1. Parker KL, Lee PA. Depot leuprolide acetate for treatment of precocious puberty. The Journal of clinical endocrinology and metabolism. 1989;69(3):689–91. doi: 10.1210/jcem-69-3-689. - DOI - PubMed
    1. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F. et al.Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. European journal of endocrinology/European Federation of Endocrine Societies. 1999;141(2):140–4. - PubMed
    1. Brauner R, Adan L, Malandry F, Zantleifer D. Adult height in girls with idiopathic true precocious puberty. The Journal of clinical endocrinology and metabolism. 1994;79(2):415–20. doi: 10.1210/jc.79.2.415. - DOI - PubMed

Associated data